tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Mar 6;10(3):402.
doi: 10.3390/vaccines10030402.
HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
Juan Francisco Gutiérrez-Bautista[SUP] 1 2 [/SUP], Antonio Sampedro[SUP] 3 [/SUP], Esther Gómez-Vicente[SUP] 3 [/SUP], Javier Rodríguez-Granger[SUP] 3 [/SUP], Juan Antonio Reguera[SUP] 3 [/SUP], Fernando Cobo[SUP] 3 [/SUP], Francisco Ruiz-Cabello[SUP] 1 4 5 [/SUP], Miguel Ángel López-Nevot[SUP] 1 4 5 [/SUP]
Affiliations
Abstract
The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273.
Keywords: HLA associations; anti-S antibodies; mRNA-1273 vaccine.
. 2022 Mar 6;10(3):402.
doi: 10.3390/vaccines10030402.
HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
Juan Francisco Gutiérrez-Bautista[SUP] 1 2 [/SUP], Antonio Sampedro[SUP] 3 [/SUP], Esther Gómez-Vicente[SUP] 3 [/SUP], Javier Rodríguez-Granger[SUP] 3 [/SUP], Juan Antonio Reguera[SUP] 3 [/SUP], Fernando Cobo[SUP] 3 [/SUP], Francisco Ruiz-Cabello[SUP] 1 4 5 [/SUP], Miguel Ángel López-Nevot[SUP] 1 4 5 [/SUP]
Affiliations
- PMID: 35335034
- DOI: 10.3390/vaccines10030402
Abstract
The vaccines designed against the SARS-CoV-2 coronavirus are based on the spike (S) protein. Processing of the S protein by antigen-presenting cells (APC) and its subsequent presentation to T cells is an essential part of the development of a humoral response. HLA-class II alleles are considered immune response genes because their codified molecules, expressed on the surface of APCs (macrophages, dendritic, and B cells) present antigenic peptides to T cell via their T cell receptor (TCR). The HLA-class II genes are highly polymorphic, regulating what specific peptides induce follicular helper T cells (TFH) and promote B lymphocyte differentiation into plasma or memory B cells. This work hypothesizes that the presence of certain HLA-class II alleles could be associated with the intensity of the humoral response (amount, length) to the SARS-CoV2 mRNA 1273 vaccine. We have studied the relationship between the HLA-class II typing of 87 health workers and the level of antibodies produced 30 days after vaccination. We show a possible association between the HLA-DRB1* 07:01 allele and the HLA-DRB1*07:01~DQA1*02:01~DQB1*02:02 haplotype to a higher production of antibodies 30 days after the administration of the second dose of mRNA-1273.
Keywords: HLA associations; anti-S antibodies; mRNA-1273 vaccine.